Letrozole as a Treatment of Endometrial Cancer

Status Completed

Clinical Trial Summary

Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00997373
Study type	Interventional
Source	University of California, Davis
Contact
Status	Completed
Phase	N/A
Start date	October 2009
Completion date	September 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Completed	`NCT00729586` - Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	Phase 2
Completed	`NCT00756847` - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors	Phase 1
Completed	`NCT02983279` - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer	N/A
Completed	`NCT02017353` - Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma	Phase 2
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Recruiting	`NCT04576104` - Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer	Phase 2
Not yet recruiting	`NCT06102252` - Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma	N/A
Active, not recruiting	`NCT02598219` - Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.	Phase 3
Recruiting	`NCT04159155` - A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	Phase 2/Phase 3
Recruiting	`NCT05139368` - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer	N/A
Recruiting	`NCT02611024` - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors	Phase 1/Phase 2
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Suspended	`NCT06253494` - Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03917381` - GEN1046 Safety Trial in Patients With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03372720` - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors	N/A
Recruiting	`NCT06413992` - Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer	Phase 2
Recruiting	`NCT05316467` - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma	Phase 2/Phase 3
Active, not recruiting	`NCT03752398` - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)	Phase 1